个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共8条记录   NADPH oxidase inhibitors: a patent review [作者：Kim, JA; Neupane, GP; Lee, ES; Jeong, BS; Park, BC; Thapa, P,期刊：Expert Opinion on Therapeutic Patents, 页码：1147-1158 , 文章类型： Review，,卷期：2011年21-8] Introduction: NADPH oxidases, a family of multi-subunit enzyme complexes, catalyze the production of reactive oxygen species (ROS), which may contribute to the pathogenesis of a variety of diseases. In addition to the fi... Carboxylesterase inhibitors [作者：Hatfield, MJ; Potter, PM,期刊：Expert Opinion on Therapeutic Patents, 页码：1159-1171 , 文章类型： Review，,卷期：2011年21-8] Introduction: Carboxylesterases play major roles in the hydrolysis of numerous therapeutically active compounds. This is, in part, due to the prevalence of the ester moiety in these small molecules. However, the impact t... New first and second generation inhibitors of human immunodeficiency virus-1 integrase [作者：Pendri, A; Meanwell, NA; Peese, KM; Walker, MA,期刊：Expert Opinion on Therapeutic Patents, 页码：1173-1189 , 文章类型： Review，,卷期：2011年21-8] Introduction: The use of inhibitors of HIV-1 integrase for treating HIV-1 infection has proven to be very beneficial. Raltegravir, a strand transfer inhibitor, has been approved for use both as a first-line therapy and i... Checkpoint kinase inhibitors: a patent review (2009-2010) [作者：Lainchbury, M; Collins, I,期刊：Expert Opinion on Therapeutic Patents, 页码：1191-1210 , 文章类型： Review，,卷期：2011年21-8] Introduction: Cells that suffer DNA damage activate the checkpoint kinases CHK1 and CHK2, which signal to initiate repair processes, limit cell-cycle progression and prevent cell replication, until the damaged DNA is rep... A survey of small molecule glucagon receptor antagonists from recent patents (2006-2010) [作者：Shen, DM; Lin, SNA; Parmee, ER,期刊：Expert Opinion on Therapeutic Patents, 页码：1211-1240 , 文章类型： Review，,卷期：2011年21-8] Introduction: The ever increasing prevalence of type 2 diabetes mellitus (T2DM) in the developed and developing nations calls for the introduction of new and more effective treatments. Glucagon receptor (GCGR) antagonist... Aminopeptidase N (EC 3.4.11.2) inhibitors (2006-2010): a patent review [作者：Su, L; Fang, H; Xu, WF,期刊：Expert Opinion on Therapeutic Patents, 页码：1241-1265 , 文章类型： Review，,卷期：2011年21-8] Introduction: Aminopeptidase N (APN/CD13) acts as an exopeptidase and has been studied for decades. In recent years, it has been seen not only as a tumor-related target but also as a potential functional protein in vario... 4-Azetidinyl-1-heteroatom linked cyclohexane antagonists of CCR2: patent evaluation [作者：Horuk, R; Guilford, W,期刊：Expert Opinion on Therapeutic Patents, 页码：1275-1280 , 文章类型： Article，,卷期：2011年21-8] This application discloses a series of di- and tri-substituted cyclohexanes as CCR2 receptor antagonists which are stated to be useful in treating inflammation and autoimmune diseases, such as type 2 diabetes and asthma.... Parthenogenetically activated human oocytes and parthenogenetic embryonic stem cells: US20100233143 [作者：Taupin, P,期刊：Expert Opinion on Therapeutic Patents, 页码：1281-1283 , 文章类型： Article，,卷期：2011年21-8] Background: The application (US20100233143) is in the field of embryonic stems cells (ESCs) and the generation of ESCs from parthenogenetically activated human oocytes.Objective: It aims at determining optimal conditions...